TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVA) Free cash flow 2016–2025
TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVA) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
$1.1BFY2025 · since FY2016: $3.0B → $1.1B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $1.1B | +53.3% |
| FY2024 | $749.0M | -11.0% |
| FY2023 | $842.0M | -19.2% |
| FY2022 | $1.0B | +341.5% |
| FY2021 | $236.0M | -63.0% |
| FY2020 | $638.0M | +186.1% |
| FY2019 | $223.0M | -87.6% |
| FY2018 | $1.8B | +32.9% |
| FY2017 | $1.4B | -54.8% |
| FY2016 | $3.0B | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More TEVA financial trends
TEVA RevenueTEVA Net incomeTEVA Net marginTEVA Gross profitTEVA Gross marginTEVA Operating incomeTEVA Operating marginTEVA Operating cash flowTEVA Capital expendituresTEVA Return on equityTEVA Stock buybacksTEVA Dividends paidTEVA Total assetsTEVA Total liabilitiesTEVA Shareholders’ equityTEVA overview →